Zentalis Lawsuit Submission Form | StockFraudLawCenter

First Name

Last Name

Phone

Street Address

City

State

Zip

Shares Owned

Purchase Date

Estimated Loss

Stock Fraud Law Center does not share your information with others. There is no cost or obligation for you to submit.

Investigation Details

Zentalis announced on June 18, 2024, that “the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the following studies of azenosertib: the Phase 1 ZN-c3-001 dose-escalation study in solid tumors, the Phase 2 ZN-c3-005 (DENALI) study in platinum-resistant ovarian cancer (PROC) and the Phase 2 ZN-c3-004 (TETON) study in uterine serous carcinoma (USC).”

Following this news, Zentalis’s stock price fell over 50% on June 18, 2024.

Active Cases

Ticker Symbol	Company Name	Join Deadline	Join
UPS	United Parcel Service, Inc.	December 09, 2024	Join
EW	Edwards Lifesciences Corporation	December 13, 2024	Join
TD	The Toronto-Dominion Bank	December 23, 2024	Join
WOLF	Wolfspeed, Inc.	January 17, 2025	Join

Zentalis Pharmaceuticals, Inc.

ZNTL

Zentalis Pharmaceuticals, Inc. Form

Active Cases